会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • SOLID-STATE FORM OF AMG 706 AND PHARMACEUTICAL COMPOSITIONS THEREOF
    • AMG 706的固体状态及其药物组合物
    • US20100331548A1
    • 2010-12-30
    • US12875844
    • 2010-09-03
    • Belle B. LiuGonzalo AlvaNina CauchonSeshadri NeervannanPengzu Zhou
    • Belle B. LiuGonzalo AlvaNina CauchonSeshadri NeervannanPengzu Zhou
    • C07D401/14B29B9/00
    • C07D401/14
    • The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    • 抗血管生成药物AMG 706以无定形形式提供。 还提供了AMG 706药物物质,其中AMG 706以至少可检测的量存在,作为无定形AMG 706。还提供了一种AMG 706-结晶抑制剂复合物,其包含无定形AMG 706或AMG 706药物物质的颗粒 本发明与一种或多种结晶抑制剂(例如聚合物)紧密结合。 还提供了包含这种AMG 706-结晶抑制剂复合物和一种或多种赋形剂的药物组合物。 还提供了制备本发明的无定形AMG 706,AMG 706药物物质,本发明的AMG 706-结晶抑制剂复合物和本发明的药物组合物的方法。 还提供了一种治疗受试者的医疗状况或病症的方法,其中指示用抗血管生成药物治疗,包括以治疗有效量施用例如口服本发明组合物。
    • 4. 发明申请
    • Solid-state form of AMG 706 and pharmaceutical compositions thereof
    • AMG 706的固体形式及其药物组合物
    • US20080108664A1
    • 2008-05-08
    • US11636183
    • 2006-12-07
    • Belle B. LiuGonzalo AlvaNina CauchonSeshadri NeervannanPengzu Zhou
    • Belle B. LiuGonzalo AlvaNina CauchonSeshadri NeervannanPengzu Zhou
    • A61K31/4439C07D401/14
    • C07D401/14
    • The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    • 抗血管生成药物AMG 706以无定形形式提供。 还提供了AMG 706药物物质,其中AMG 706以至少可检测的量存在,作为无定形AMG 706。还提供了一种AMG 706-结晶抑制剂复合物,其包含无定形AMG 706或AMG 706药物物质的颗粒 本发明与一种或多种结晶抑制剂(例如聚合物)紧密结合。 还提供了包含这种AMG 706-结晶抑制剂复合物和一种或多种赋形剂的药物组合物。 还提供了制备本发明的无定形AMG 706,AMG 706药物物质,本发明的AMG 706-结晶抑制剂复合物和本发明的药物组合物的方法。 还提供了一种治疗受试者的医疗状况或病症的方法,其中指示用抗血管生成药物治疗,包括以治疗有效量施用例如口服本发明组合物。